Abstract
Introduction
Drug-induced QT prolongation increases the risk for torsade de pointes, a potentially fatal ventricular arrhythmia, and has resulted in drugs being removed from the market [1] . The current regulatory paradigm for assessing drug cardiac safety, which is extremely focused on QT prolongation, is preventing potentially effective medicines from reaching the market, sometimes inappropriately [1] . To address this safety issue, the US Food and Drug Administration (FDA) and multiple public-private partnerships are studying novel approaches with a Comprehensive in vitro Proarrhythmia Assay and in Phase 1 clinical trials [2, 3] . Essential to the novel approaches is a focus on the effects of drugs on multiple cardiac ion channels, which can be either pro-or antiarrhythmic, depending on the combination.
Almost all drugs that may cause torsade de pointes block the hERG potassium channel. As a consequence, the outward potassium current is reduced at the cellular level and the QT interval is prolonged on the electrocardiogram (ECG) [4] . However, for some of these drugs the torsade de pointes risk is minimal [5] .
In addition to the QTc interval (heart rate corrected QT), other ECG biomarkers have been introduced to measure the effect of ion channel blocks. Of note, in the context of this paper, is the ECG-interval from the Twave peak to its end (T p T e ). hERG block also affects the morphology of the T-wave; various markers have been proposed to measure those changes, which cause some variability in the measurement of T-wave peak, needed for T p T e , and in general making its significance difficult to interpret.
Hypokalemia in some respects mimics hERG channel block in that it also causes a reduced potassium outflow current. Besides QT prolongation, classic ECG hallmark of hypokalemia is a reduced T-wave amplitude [6] , while the opposite (hyperkalemia) is traditionally diagnosed as tall, peaked T-waves [7] . We recently proposed a metric to quantify the plasma potassium concentration [8] , based on the ratio of down-going T-wave slope and T-wave amplitude (T S/A ) and tested it on patients undergoing haemodialysis. The relationship between this metric and blood plasma potassium concentration suggested that the metric could actually measure outward potassium current. This hypothesis was confirmed by model studies and measurements on LQT2-patients [8] . Incidentally, the same study showed that T S/A was not sensitive to the, sometimes extensive, calcium (Ca) and sodium (Na) concentration changes during the dialysis. The observation has led us to evaluate T S/A in the context of drug safety studies as an alternate metric of the amount of hERG block, independent from Na and Ca channel block.
2.

Method
We used data from two previous clinical studies, both similar in design to dedicated QT studies [9] , in which 22 young volunteers without ECG or apparent cardiovascular abnormalities participated. The studies were designed as a randomized, double-blind, 5-period crossover clinical trials at a phase 1 clinical research unit (Spaulding Clinical, West Bend, WI). Subjects were "dosed" with a combination of drugs or placebo, depending on the trial, either at the beginning of the 24 hour measurement period or at various time points in the morning, afternoon and evening, and blood samples for drug concentration measurements were taken at various time points. Subjects repeated the recording period at consecutive weeks to complete the 5 arms of the study. During each period, continuous ECGs were recorded at 500 Hz and with an amplitude resolution of 2.5 µV (Mortara Instrument, Milwaukee). From the continuous recording, triplicate 10-second ECGs were extracted at predose and 15 other time points including those of the blood draws using Antares software (AMPS-LLC, New York City). The studies were approved by the U.S. FDA Research Involving Human Subjects Committee and the local institutional review board. All subjects gave written informed consent. ECG's and drug concentrations have been made available in Physionet [10] : https://physionet.org/physiobank/database/ecgrdvq/.
The first study has been described in [11, 12] . The study is identified in the data description file in Physionet and this paper as "002". The second study, identified as "003", uses different drugs and doses [13] ; see: https://physionet.org/physiobank/database/ecgdmmld/.
We re-analyzed all ECG's from the raw data samples with the Mortara Instrument VERITAS resting ECG interpretation program, to which we had added a module to calculate the T S/A parameter. The principle of the calculation has been described previously [8, 14] . For this study, we used the vector magnitude of all independent leads as input for the calculation, but similar results were obtained using only leads I and II.
We compared T S/A with a diverse number of ECGmetrics which were provided for each ECG in the data description files available on Physionet. Their meaning is described in [11] [12] [13] We focused on the metrics that resulted from these previous studies as mostly sensitive to hERG block, and the least affected by sodium (Na) blocking agents [16] : LRD 30% (the time it takes for the Tvector amplitude to decrease 30% after the peak) and the T p T e ; as a reference we used the QTc interval. For RRcorrection of the QT-interval, Fredericia's correction (QTc = QT/(RR/1000 ms) 1/3 ) was used. Other parameters, including T S/A were not corrected for RR. For all measurements, we have taken the median of the three ECG's provided at each time point.
From each drug plasma concentration, we calculated the estimated %hERG block with the Hill equation:
where B(%) is the percentage of current blockage at drug concentration D, IC 50 is the concentration of drug that causes 50% block, and n is the Hill coefficient. The IC 50 and n values for each drug were obtained from data in [16] . In the case of moxifloxacin, the effect of its glucuronide metabolite (M2) that exhibits hERG potassium channel block has been taken into account: based on previous observations [13, 17] we considered for M2 a 5% protein binding and hERG block parameters equal to those of the parent drug. We used 0% block for all time points with placebo and for those where only drugs with no known hERG block were used, and we did not use any data points without available plasma concentrations.
In order to exclude any subject and time-of-day dependencies, we applied a "Delta-Delta" (∆∆) design, that is, we subtracted from each time point the values for the same subject at pre-dose, as well as the values for the "Delta" at corresponding time points in the placebo arm.
Results
Study 002 was designed as a single dose study that sampled the subject during the following gradual increase and subsequent decrease of drug plasma concentration. Four drugs were used: dofetilide, a pure hERG channel blocker; quinidine, with stronger hERG channel block and, at higher concentrations, also some calcium (Ca) and Na channel blocks; ranolazine with a moderate hERG block together with an equal amount of Na channel block; verapamil with little hERG block but a higher amount of Ca channel block. An example of a scatter plot of the ∆∆ samples as a function of %hERG block (calculated from the measured plasma concentration) for QT c and T S/A in the quinidine arm of the study is shown in Fig. 1 .
Some of the metrics were clearly non-linear to %hERG block, and also the spread around the mean depends on the drug and the actual %hERG block. In order to compare metrics under various %hERG block, we divided the data points (e.g. those in Fig. 1 ) into four groups: little or no (<10%) block, small (10-30%) block, medium (30-50%) block, and large (>50%) block. We then calculated the average value of each of the metrics in each group. As a measure of confidence, we calculated the standard deviation (SD) of the difference between the data and a linear regression line through the origin, per group. We converted the response of all metrics to "%hERG" using the response to the medium (30-50%) amount of hERG block by dofetilide, a pure potassium blocker, as a normalizing scale factor. Study 003 had a more complicated dosing scheme [17] which resulted in time points being available only around the period of maximum plasma concentration of any given drug combination. Arms 1-3 used dofetilide as the hERG channel blocker, by itself, or in combination with lidocaine or mexiletine, mostly Na channel blockers. The morning dose did not contain any dofetilide; the afternoon and evening doses contained increasing amounts of all drugs. In the fourth arm, moxifloxacin was used, to which diltiazem was added in the evening dose. Moxifloxacin mostly blocks the hERG potassium channels, while diltiazem is a Ca channel blocker. We did the same analysis as for the previous study data. We found that the %hERG gain for dofetilde was somewhat lower than in the previous study for all markers, so we recalibrated the translation to %hERG block by the response to dofetilide.
Combined results can be seen in Figure 2 . All groups from both studies with at least 60 raw data samples are shown, except the response to 30-50%hERG block by dofetilide alone, used for normalization. The standard deviations are scaled such that they indicate the 95% confidence interval of a 60 data point sample.
In Table 1 , the SD of each of the metrics is shown as a function of the amount of %hERG block.
Discussion and Conclusions
The response of all ECG metrics to pure hERG blockers (dofetilide and quinidine) is non-linear: the ECG-estimate at high plasma concentrations is clearly too high (Fig. 2 and , group>50%). T S/A has less overestimation than the other metrics. LRD 30% and T p T e particularly overestimate at high quinidine concentrations.
As is known from previous work (13, 15) , QTc consistently under-estimates hERG block in the presence of sodium blockers (Fig 2, ranolazine, lidocaine or mexiletine,), while T S/A , T p T e and LRD 30% do not.. When normalized by dofetilide, LRD 30% underestimates the amount of hERG block of moxifloxacine (Fig 2, ) . The addition of the calcium blocker diltiazem increased QTc, T p T e and LRD 30% , but T S/A was affected little (Fig 2, ) . A low variability is important for the ECG biomarkers, in order to keep the number of subjects in a study as low as possible. It can be seen from table 1 that QTc and T S/A have similar average standard deviations, but T p T e is 50% higher, and LRD 30% three times as high. This is caused in particular by the cases of a higher amount of hERG block. The variability of T S/A is not affected by %hERG block.
In conclusion, T S/A clearly outperforms the other two ECG metrics T p T e and LRD 30% as a measure of %hERG block. T S/A is not affected by Na and Ca blockers, and independent of the type of drug, T S/A is more stable than T p T e and LRD 30% , in particular at high amounts of %hERG block where variation in T-wave morphology is present, like with quinidine.
T S/A is a fully automatically calculated metric. It is stable and not affected by morphology changes like notches and double peaks because there is no need to precisely measure the timing of landmarks like T-wave peak or end. The measurement is robust and not susceptible to artifact. Like T p T e and LRD 30% , the metric focuses on the latter part of the T-wave and, like T p T e and LRD 30% , its dimension is that of (inverted) time.
We propose that T S/A be one of the metrics used in early Phase 1 exposure-response modeling studies to determine if there are unexpected effects compared to preclinical ion channel data, which might occur due to a human-specific metabolite or protein binding, as part of the Comprehensive in vitro Proarrhythmia Assay (CiPA) paradigm [2] .
